anti-GD2 CAR T-cell therapy (University of Colorado/University of North Carolina)

N/A

Report date: 2025/01/26 18:54:13

Base Information

Drug Nameanti-GD2 CAR T-cell therapy (University of Colorado/University of North Carolina)
Drug Alias NameIL-15 expressing anti-GD2 CAR T-cell therapy (University of Colorado/University of North Carolina)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-15 receptors agonists
TargetsInterleukin-15 receptors
Therapy Area/IndicationsRetinoblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Colorado
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Colorado
Inactive CompaniesN/A
Active IndicationsRetinoblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A